Peptide · Fact sheet

BPC-157

Also known as Body Protection Compound 157

BPC-157 is often promoted for injury or gut healing, but it is not an FDA-approved medicine and reliable human clinical evidence is extremely limited.

In clinical trialsMostly animal or lab research

What is BPC-157?

BPC-157 is a synthetic sequence described as being derived from a gastric protein fragment.

Claims about healing are largely extrapolated from animal and laboratory studies, which cannot show that the same benefits or risks apply to people.

Benefits & claims

Online discussions frequently mention tendon, ligament, muscle, bone, nerve, and gastrointestinal recovery.

The gap between confident marketing and sparse human evidence is the central fact readers should understand.

What the evidence supports

  • Animal and laboratory studies have reported signals related to tissue repair and inflammation.
  • Those findings are hypotheses for human research, not proven patient benefits.
Research areas
  • Acute hamstring strain in a registered Phase 2 trial
  • Tissue repair in animal models
  • Gastrointestinal effects in animal models
  • Inflammation and blood-vessel signaling in preclinical research
  • Acute hamstring-strain repair in a registered trial
  • Preclinical models of tissue injury and gastrointestinal conditions

Dosage & frequency

No established human regimen

There is no established human dosage or frequency for BPC-157 injury repair. A registered trial is a research plan, not proof of an effective treatment regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • BPC-157 is an experimental peptide; oral, injected, and other formulations cannot be assumed equivalent.

Interactions & precautions

  • Controlled human interaction data are insufficient for BPC-157; animal repair findings do not establish compatibility with medicines.

What is still unresolved

  • Controlled human efficacy, route-specific exposure, repeated-use safety, and interaction data are still inadequate.

Side effects & risks

  • Human short- and long-term safety are poorly characterized.
  • FDA notes possible immune reactions, peptide-related impurities, and difficulty characterizing the active ingredient.
  • Unapproved products may introduce contamination, incorrect-strength, sterility, or mislabeling risks.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

Most cited work is preclinical. There is no mature body of randomized human trials establishing safety and effectiveness for common promoted uses.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Negative account · personal report

Nausea, fatigue, anxiety and fainting

A separate poster described nausea, marked tiredness, increased anxiety and passing out during exercise after starting a product labeled BPC-157.

Reported use in this account

Product
Product described as BPC-157
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Three days

The product and reported fainting episode were not independently verified. The amount unit in a reply cannot be resolved, so no usable amount is shown; the source does not establish an allergic mechanism.

Read the separate BPC-157 account

Approval status

BPC-157 is not FDA approved. A Phase 2 hamstring-strain trial is registered, and FDA lists BPC-157 among bulk substances for which compounded products may present significant safety risks and for which safety information is limited.

Early human clinical testing

A Phase 2 hamstring-strain trial is registered, but no BPC-157 product is FDA approved and the published evidence base remains mostly preclinical.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether animal findings translate to meaningful human benefits
  • Long-term safety, cancer-related signaling concerns, interactions, and reproductive risks
  • A reliable adverse-effect rate or risk profile
  • Whether products sold under the name consistently contain the claimed substance

Summary

BPC-157 has preclinical tissue-repair findings, but controlled human evidence and safety data remain limited.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: bulk substances that may present significant safety risks

    FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.

  2. clinical trialsClinicalTrials.gov: BPC-157 hamstring strain study

    Registry record for an early human BPC-157 study, not evidence of established clinical benefit.

  3. pubmedBPC-157 preclinical gastrointestinal review

    Peer-reviewed review focused largely on preclinical BPC-157 research.

  4. pubmedBPC-157 wound-healing review

    Review discussing BPC-157 wound-healing research, primarily outside mature human efficacy trials.

How we assess sources · Suggest a correction